Comparison
Piracetam vs Nefiracetam
Piracetam
The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. A cyclic derivative of GABA and the founding member of the racetam family.
Nefiracetam
Fat-soluble racetam developed in Japan with GABAergic anxiolytic + cholinergic memory effects.
| Field | Piracetam | Nefiracetam |
|---|---|---|
| Category | racetam | racetam |
| Dose range | 1200–4800mg | 150–450mg |
| Half-life | 5h | 4h |
| Onset | 45min | — |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●●● | ●●●○○ |
| Legal (US) | USUnscheduled | USUnscheduled |
| PubMed refs | 1200 | 30 |
The comparison in plain English
Auto-generated from dataPiracetam and Nefiracetam are both in the racetam category respectively. Piracetam The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. Nefiracetam Fat-soluble racetam developed in Japan with GABAergic anxiolytic + cholinergic memory effects.
Bottom line
Piracetam (evidence A, safety 5/5) has a weaker evidence base than Nefiracetam (evidence B, safety 3/5). Piracetam has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Piracetam if
Piracetam is the better fit when your goal aligns with its mechanism (Modulates AMPA and NMDA glutamate receptors and enhances acetylcholine signaling via muscarinic receptor allosteric modulation) and the dose range (1200–4800mg) suits your protocol. Half-life is 5h.
Choose Nefiracetam if
Nefiracetam is the better fit when your goal aligns with its mechanism (Enhances NMDA and nicotinic acetylcholine receptor function and produces mild GABAergic potentiation) and the dose range (150–450mg) suits your protocol. Half-life is 4h.